All News
Filter News
Found 65,044 articles
-
Notice of Annual General Meeting in Cantargia AB (publ) - April 18, 2024
4/18/2024
Cantargia The shareholders of Cantargia AB are invited to the annual general meeting on Thursday, 23 May 2024, at 15.00 CEST at Ideon Gateway, Scheelevägen 27, Lund, Sweden.
-
Metsera Launches to Lead the Next Generation of Medicines for Obesity and Metabolic Diseases
4/18/2024
Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, announced its launch today.
-
Cellares Launches Cell Q, the World’s First Automated cGMP QC Workcell for Cell Therapies, to Resolve Manual QC Processing Bottleneck and Extend IDMO Capabilities from Manufacturing Through Quality Control
4/18/2024
Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, today unveiled Cell Q™, the first automated quality control (QC) workcell for cell therapy manufacturing.
-
Hansa Biopharma interim report January-March 2024
4/18/2024
Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, announced its business update and year-end report for January to March 2024.
-
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
4/18/2024
NKGen Biotech, Inc. announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details around its NK cell therapy in neurodegenerative disease.
-
Windtree Therapeutics Announces Reverse Stock Split - April 18, 2024
4/18/2024
Windtree Therapeutics, Inc. today announced that the Company’s Board of Directors has approved a 1-for-18 reverse stock split of its issued and outstanding common stock, par value of $0.001 per share (the “Reverse Stock Split”).
-
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation
4/18/2024
BioVie Inc. today announced that an oral presentation and poster presentation will be shared at the 12th Annual Alzheimer's &Parkinson's Drug Development Summit to be held in Boston, Massachusetts April 23-25.
-
Henry Schein Supports The ‘Carry The Load’ Memorial May Campaign For Third Consecutive Year
4/18/2024
Henry Schein, Inc. (Nasdaq: HSIC) today announced that for the third consecutive year it is supporting the Carry The Load ® Memorial May campaign, a month-long Memorial Day awareness program providing active ways to connect Americans to the sacrifices made by the U.S. military, veterans.
-
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
4/18/2024
Lumos Pharma, Inc. (NASDAQ:LUMO) announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe.
-
As its lead oral targeted protein degrader moves through Phase III in partnership with Pfizer, Arvinas signs a licensing deal handing over all rights and responsibilities to Novartis.
-
Inflammatory disease–focused Mirador Therapeutics landed the largest early-stage VC investment in biopharma last quarter, as more companies are securing $150 million or more.
-
The Menlo Park, Calif.-based venture capital firm has raised more than $1 billion since last year, with this latest injection of capital going to its biopharma investment funds.
-
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
4/17/2024
ABVC BioPharma, Inc. announced today that the Company, together with its affiliate Rgene Corporation entered into a comprehensive licensing agreement with OncoX.
-
Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study
4/17/2024
Hyperfine, Inc. today announced that the first patients have been enrolled in the CARE PMR (Capturing ARIA Risk Equitably with Portable MR) observational study.
-
Life Science Tools Market Size Set to Soar USD 367.16 Billion by 2032
4/17/2024
According to recent study by Towards Healthcare, the life science tools market size was valued at USD 111.28 billion in 2022 and is poised to exceed USD 367.16 billion by 2032, expanding at a CAGR of 13% between 2023 and 2032.
-
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
4/17/2024
Allarity Therapeutics, Inc today announced that it had been granted an extension until May 14, 2024, to regain compliance with Nasdaq Listing Rule 5550(b)(1).
-
Biochip Market Size to Hit Around USD 40.49 Billion By 2033
4/17/2024
According to Nova One Advisor, the global biochip market size was estimated at USD 12.28 billion in 2023 and is projected to hit around USD 40.49 billion by 2033, growing at a CAGR of 12.67% during the forecast period from 2024 to 2033.
-
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
4/17/2024
Windtree Therapeutics, Inc. today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided key business updates.
-
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
4/17/2024
Longeveron Inc. today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares.
-
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock - April 17, 2024
4/17/2024
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it intends to offer to sell shares of its common stock in an underwritten public offering.